Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.51 |
| ▸ | SRC | P12931 | 13/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.46 |
| ▸ | YES1 | P07947 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.46 |
| ▸ | CIT | O14578 | 1/20 | 0.42 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.42 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2883089 | 0.89 | ABL1 (0.44) | ABL1SRCCNR1PDGFRBYES1 | |
| SCHEMBL612970 | 0.83 | SRC (0.62) | ABL1SRCPDGFRBYES1KDR | |
| SCHEMBL613380 | 0.81 | DRD2 (0.44) | ABL1SRCPDGFRBYES1KDR | |
| SCHEMBL40869 | 0.79 | SRC (0.52) | ABL1SRCPDGFRBYES1KDR | |
| SCHEMBL41896 | 0.77 | SRC (0.48) | ABL1SRCPDGFRBYES1KDR | |
| SCHEMBL614557 | 0.77 | SRC (0.63) | ABL1SRCPDGFRBYES1KDR | |
| SCHEMBL613379 | 0.77 | LRRK2 (0.47) | ABL1SRCPDGFRBYES1KDR | |
| SCHEMBL42350 | 0.77 | SRC (0.51) | ABL1SRCPDGFRBYES1KDR | |
| SCHEMBL615134 | 0.76 | SRC (0.53) | ABL1SRCPDGFRBYES1KDR | |
| SCHEMBL611762 | 0.76 | SRC (0.53) | ABL1SRCPDGFRBYES1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041195-A1 | Heterocyclic compounds | FOVEA PHARMACEUTICALS | 2012-02-16 | — | — | US | claimed |
| US-20120041195-A1 | Heterocyclic compounds | FOVEA PHARMACEUTICALS | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041195-A1 | Heterocyclic compounds | MAP3K1, MAP3K5, MAP3K2 | ABL1 913/4885SRC 1204/4885CNR1 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.